Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations

More about Open Access at the Crick

Authors list

Elen Kristine Höglander Silje Nord David C Wedge Ole Christian Lingjaerde Laxmi Silwal-Pandit Hedda vdL Gythfeldt Hans Kristian Moen Vollan Thomas Fleischer Marit Krohn Ellen Schlitchting Elin Borgen Øystein Garred Marit M Holmen Erik Wist Bjørn Naume Peter Van Loo Anne-Lise Børresen-Dale Olav Engebraaten Vessela Kristensen
Scroll for detail on labs, facilities & authors

Abstract

Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits its receptor interaction, thus obstructing the formation of new blood vessels.

Journal details

Journal Genome Medicine
Volume 10
Issue number 1
Pages 92
Available online
Publication date

Full text links

Publisher website (DOI) 10.1186/s13073-018-0601-y
Figshare View on figshare
Download Download full text [pdf]
Europe PubMed Central 30497530
Pubmed 30497530

Keywords

Related topics
Type of publication

Crick labs/facilities

Crick authors

Crick First author
Crick Corresponding author

Related content